Proliferating Cell Nuclear Antigen (PCNA) is a protein present in all eukaryotic cells that plays a crucial role in DNA synthesis and repair. It is widely used as a biomarker for tumor progression and is also considered a potential target for cancer therapy. Small molecule targeting of transcription-replication conflict for selective chemotherapy"Holy grail" moleculeRecently, a team from City of Hope in California, United States, published a study showing that a new type of anticancer drug targ

Immunotherapy combining immune checkpoint inhibitors (ICIs) with anti-angiogenesis tyrosine kinase inhibitors (TKIs) has been shown to improve overall survival compared to anti-angiogenesis therapy alone in advanced solid tumors, but not in hepatocellular carcinoma. Dynamic duoRecently, a study has been published in The Lancet, which conducted a clinical trial comparing the efficacy and safety of the anti-PD-1 antibody camrelizumab combined with the VEGFR2-targeted TKI rivoceranib (also known a

Esophageal squamous cell carcinomaThe Chinese Academy of Sciences' Center for Systems Biology recently published a research article in Nature Medicine titled "Neoadjuvant Adebrelimab in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma: A Phase 1b Trial," which reports on the results of the world’s first-ever neoadjuvant mono-immunotherapy Phase 1b clinical trial of locally advanced esophageal squamous cell carcinoma. The study proposes new strategies for predicting tumor immunother

Different types of extracellular vesiclesOn July 12, Direct Biologics has announced positive safety and efficacy results from its Phase 2 clinical trial (NCT04493242) of ExoFlo in adult COVID-19 patients with moderate-to-severe acute respiratory distress syndrome (ARDS). EVs for COVIDThe Texas-based biotech company has conducted a randomized, double-blind, placebo-controlled clinical trial to investigate the efficacy and safety of extracellular vesicles (EVs) derived from bone marrow mesenchym

Bispecific antibodies (BsAbs) are recombinant molecules that contain two different antigens or epitopes identifying binding domains. They have gained broad potential in preclinical and clinical investigations in a variety of tumor types following regulatory approval of newly developed technologies involving bispecific and multispecific antibodies. CD3+ bispecific T-cell engaging antibodies exert function in Hematological Malignancies and recruit immune cells into the solid tumor microenvironme

The roles and mechanisms of the m6A reader protein YTHDF1 in tumor biologyHepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and the third leading cause of cancer-related deaths worldwide. The development of HCC is influenced by both viral and non-viral factors. Non-alcoholic steatohepatitis (NASH) has emerged as a growing risk factor for HCC, as the prevalence of diabetes and metabolic syndrome increases. NASH is a progressive liver disease characterized by the accumulat

USP1 Inhibitor binding disrupts the catalytic siteKSQ Therapeutics has entered a worldwide licensing and collaboration agreement with Roche for the development and commercialization of KSQ-4279, a first-in-class, potent, and selective small molecule inhibitor of USP1. USP1 is a protein that regulates the DNA damage response (DDR) in a novel way distinct from other approaches, including PARP inhibitors. The molecule is currently in Phase 1 clinical trials for the treatment of solid tumors. 

In Alzheimer's disease, characteristic changes occur in the brain. Senile plaques consisting of the protein beta-amyloid (shown in brown) and neurofibrillary tangles consisting of the protein tau are formed.Scientists from Southern Medical University of China have discovered new evidence suggesting that the small G protein family member, Cdc42, plays an important role in the progression of Alzheimer's disease. Alzheimer's, the most common cause of dementia, is characterized by extracellular seni

China's first drug to be approved for clinical trials using cardiac organoid-on-chips data has been granted permission in late May 2023. According to the website of the National Medical Products Administration, Hengrui Medicine's HRS-1893 tablets have been approved for clinical trials. HRS-1893 works through a special mechanism that inhibits myocardial excessive contraction and is intended for the treatment of hypertrophic cardiomyopathy and heart failure caused by myocardial hypertrophy. This m

TIGIT, a major immune checkpoint molecule, is expressed on the surface of T cells and natural killer (NK) cells. In 2002, researchers from Genentech first discovered this gene, which exhibited specific expression in T cells and NK cells. Subsequently, TIGIT made its debut in 2009 in Nature Immunology, where it was identified to possess an immunoglobulin-like (IgV) domain and an immunoreceptor tyrosine-based inhibition motif (ITIM). Scientists thus named it TIGIT (T-cell immunoreceptor with Ig